Literature DB >> 27392509

Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial).

Yazan Daaboul1, Serge Korjian1, W Douglas Weaver2, Robert A Kloner3, Robert P Giugliano4, Jim Carr5, Brandon J Neal1, Gerald Chi1, Madeleine Cochet1, Laura Goodell1, Nathan Michalak1, Luke Rusowicz-Orazem1, Turky Alkathery1, Haytham Allaham1, Sujit Routray1, Donald Szlosek1, Purva Jain1, C Michael Gibson6.   

Abstract

Biomarker measures of infarct size and myocardial salvage index (MSI) are important surrogate measures of clinical outcomes after a myocardial infarction. However, there is variability in infarct size unaccounted for by conventional adjustment factors. This post hoc analysis of Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With Acute Coronary Events (EMBRACE) ST-Segment Elevation Myocardial Infarction (STEMI) trial evaluates the association between left ventricular (LV) mass and infarct size as assessed by areas under the curve for creatine kinase-MB (CK-MB) and troponin I release over the first 72 hours (CK-MB area under the curve [AUC] and troponin I [TnI] AUC) and the MSI. Patients with first anterior STEMI, occluded left anterior descending artery, and available LV mass measurement in EMBRACE STEMI trial were included (n = 100) (ClinicalTrials.govNCT01572909). MSI, end-diastolic LV mass on day 4 cardiac magnetic resonance, and CK-MB and troponin I concentrations were evaluated by a core laboratory. After saturated multivariate analysis, dominance analysis was performed to estimate the contribution of each independent variable to the predicted variance of each outcome. In multivariate models that included age, gender, body surface area, lesion location, smoking, and ischemia time, LV mass remained independently associated with biomarker measures of infarct size (CK-MB AUC p = 0.02, TnI AUC p = 0.03) and MSI (p = 0.003). Dominance analysis demonstrated that LV mass accounted for 58%, 47%, and 60% of the predicted variances for CK-MB AUC, TnI AUC, and MSI, respectively. In conclusion, LV mass accounts for approximately half of the predicted variance in biomarker measures of infarct size. It should be considered as an adjustment variable in studies evaluating infarct size.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27392509     DOI: 10.1016/j.amjcard.2016.06.025

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Mitochondrial ROS Drive Sudden Cardiac Death and Chronic Proteome Remodeling in Heart Failure.

Authors:  Swati Dey; Deeptankar DeMazumder; Agnieszka Sidor; D Brian Foster; Brian O'Rourke
Journal:  Circ Res       Date:  2018-06-13       Impact factor: 17.367

2.  Gender but not diabetes, hypertension or smoking affects infarct evolution in ST-elevation myocardial infarction patients - data from the CHILL-MI, MITOCARE and SOCCER trials.

Authors:  David Nordlund; Henrik Engblom; Jean-Louis Bonnet; Henrik Steen Hansen; Dan Atar; David Erlinge; Ulf Ekelund; Einar Heiberg; Marcus Carlsson; Håkan Arheden
Journal:  BMC Cardiovasc Disord       Date:  2019-07-03       Impact factor: 2.298

3.  The Rise of ST-Elevation Myocardial Infarction in Women of Northeast China.

Authors:  Yihe Wang; Gary S Newsome
Journal:  Gerontol Geriatr Med       Date:  2021-02-15

4.  Interleukin-38 alleviates cardiac remodelling after myocardial infarction.

Authors:  Yuzhen Wei; Yin Lan; Yucheng Zhong; Kunwu Yu; Wenbin Xu; Ruirui Zhu; Haitao Sun; Yan Ding; Yue Wang; Qiutang Zeng
Journal:  J Cell Mol Med       Date:  2019-11-20       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.